Chronic arthritis and cardiovascular disease: Altered blood parameters give rise to a prothrombotic propensity

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 3, 2014, Pages 345-352

  Beinsberger, Jilke ^a   Heemskerk, Johan W M ^a   Cosemans, Judith M E M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Ankylosing spondylitis; Cardiovascular disease; Coagulation; Platelets; Psoriatic arthritis; Rheumatoid arthritis; TNF

Indexed keywords

CYTOKINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INTERACTION; CHRONIC ARTHRITIS; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; IMMUNE RESPONSE; LEUKOCYTE; NONHUMAN; PROTHROMBOTIC PROPENSITY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME; ARTHRITIS; BLOOD; BLOOD CLOTTING; CARDIOVASCULAR DISEASES; COMPLICATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; THROMBOCYTE COUNT; THROMBOSIS;

ARTHRITIS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; HUMANS; MEAN PLATELET VOLUME; PLATELET ACTIVATION; PLATELET COUNT; RISK FACTORS; THROMBOSIS;

EID: 84919635318     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.06.006     Document Type: Review

References (105)

1. van den Oever I.A., Sattar N., Nurmohamed M.T. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis 2014, 73:954-957.
2. Avina-Zubieta J.A., Thomas J., Sadatsafavi M., Lehman A.J., Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012, 71:1524-1529.
3. Papagoras C., Voulgari P.V., Drosos A.A. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013, 31:612-620.
4. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
5. Gonzalez A., Maradit Kremers H., Crowson C.S., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 2008, 67:64-69.
6. Versteeg H.H., Heemskerk J.W., Levi M., Reitsma P.H. New fundamentals in hemostasis. Physiol Rev 2013, 93:327-358.
7. Cosemans J.M., Angelillo-Scherrer A., Mattheij N.J., Heemskerk J.W. The effects of arterial flow on platelet activation, thrombus growth, and stabilization. Cardiovasc Res 2013, 99:342-352.
8. Gasparyan A.Y., Stavropoulos-Kalinoglou A., Mikhailidis D.P., Douglas K.M., Kitas G.D. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011, 31:153-164.
9. Gieger C., Radhakrishnan A., Cvejic A., Tang W., Porcu E., Pistis G., et al. New gene functions in megakaryopoiesis and platelet formation. Nature 2011, 480:201-208.
10. Ertenli I., Haznedaroglu I.C., Kiraz S., Celik I., Calguneri M., Kirazhi S. Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatol Int 1996, 16:5-8.
11. Boilard E., Nigrovic P.A., Larabee K., Watts G.F., Coblyn J.S., Weinblatt M.E., et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010, 327:580-583.
12. Cloutier N., Pare A., Farndale R.W., Schumacher H.R., Nigrovic P.A., Lacroix S., et al. Platelets can enhance vascular permeability. Blood 2012, 120:1334-1343.
13. Heemskerk J.W., Kuijpers M.J., Munnix I.C., Siljander P.R. Platelet collagen receptors and coagulation. A characteristic platelet response as possible target for antithrombotic treatment. Trends Cardiovasc Med 2005, 15:86-92.
14. Vasina E.M., Cauwenberghs S., Staudt M., Feijge M.A., Weber C., Koenen R.R., et al. Aging- and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. Am J Blood Res 2013, 3:107-123.
15. Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology 2009, 48:11-22.
16. Vasina E., Heemskerk J.W.M., Weber C., Koenen R.R. Platelets and platelet-derived microparticles in vascular inflammatory disease. Inflamm Allergy Drug Targets 2010, 9:346-354.
17. Van der Meijden P.E., van Schilfgaarde M., van Oerle R., Renné T., ten Cate H., Spronk H.M. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012, 10:1355-1362.
18. Smyth S.S., McEver R.P., Weyrich A.S., Morrell C.N., Hoffman M.R., Arepally G.M., et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009, 7:1759-1766.
19. Rondina M.T., Weyrich A.S., Zimmermann G.A. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res 2013, 112:1506-1519.
20. Colli S., Maderna P., Tremoli E., Colombo F., Canesi B. Platelet function in rheumatoid arthritis. Scand J Rheumatol 1982, 11:139-143.
21. Mac Mullan P.A., Peace A.J., Madigan A.M., Tedesco A.F., Kenny D., McCarthy G.M. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target. Rheumatology 2010, 49:240-245.
22. Endresen G.K. Investigation of blood platelets in synovial fluid from patients with rheumatoid arthritis. Scand J Rheumatol 1981, 10:204-208.
23. Riddle J.M., Bluhm G.B., Pitchford W.C., McElroy H., Jimenea C., Leisen J., et al. A comparative study of platelet reactivity in arthritis. Ann N Y Acad Sci 1981, 370:22-29.
24. Farr M., Scott D.L., Constable T.J., Hawker R.J., Hawkins C.F., Stuart J. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis 1983, 42:545-549.
25. Di Minno M.N., Iervolino S., Peluso R., Scarpa R., Di Minno G. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol 2012, 39:334-336.
26. Berckmans R.J., Nieuwland R., Kraan M.C., Schaap M.C., Pots D., Smeets T.J., et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther 2005, 7:R536-R544.
27. Pamuk G.E., Vural O., Turgut B., Demir M., Pamuk O.N., Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis?. Platelets 2008, 19:146-154.
28. Projahn D., Koenen R.R. Platelets: key players in vascular inflammation. J Leukoc Biol 2012, 92:1167-1175.
29. Koenen R.R., Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010, 9:141-153.
30. Schmitt-Sody M., Metz P., Klose A., Gottschalk O., Zysk S., Hausdorf J., et al. In vivo interactions of platelets and leucocytes with the endothelium in murine antigen-induced arthritis: the role of P-selectin. Scand J Rheumatol 2007, 36:311-319.
31. Lincoff A.M., Kereiakes D.J., Mascelli M.A., Deckelbaum L.I., Barnathan E.S., Patel K.K., et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001, 104:163-167.
32. Eisenhardt S.U., Habersberger J., Murphy A., Chen Y.C., Woollard K.J., Bassler N., et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009, 105:128-137.
33. Zhang H., Park Y., Wu J., Chen X., Lee S., Yang J., et al. Role of TNF-α in vascular dysfunction. Clin Sci 2009, 116:219-230.
34. Metsios G.S., Stavropoulos-Kalinoglou A., Sandoo A., van Zanten J.J., Toms T.E., John H., et al. Vascular function and inflammation in rheumatoid arthritis: the role of physical activity. Open Cardiovasc Med J 2010, 4:89-96.
35. ten Cate J.W., van der Poll T., Levi M., ten Cate H., van Deventer S.J. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 1997, 78:415-419.
36. Mantovani A., Sozzani S., Vecchi A., Introna M., Allavena P. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb Haemost 1997, 78:406-414.
37. Grignani G., Maiolo A. Cytokines and hemostasis. Haematologica 2000, 85:967-972.
38. Szekanecz Z., Koch A.E. Vascular involvement in rheumatic diseases: "vascular rheumatology". Arthritis Res Ther 2008, 10:224.
39. Dessein P.H., Joffe B.I., Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R634-R643.
40. Krishnaswamy G., Kelley J., Yerra L., Smith J.K., Chi D.S. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999, 19:91-104.
41. Jackson S.P. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med 2011, 17:1423-1436.
42. Auger J.L., Haasken S., Binstadt B.A. Autoantibody-mediated arthritis in the absence of C3 and activating Fcγ receptors: C5 is activated by the coagulation cascade. Arthritis Res Ther 2012, 14:R269.
43. Song J.J., Hwang I., Cho K.H., Garcia M.A., Kim A.J., Wang T.H., et al. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011, 121:3517-3527.
44. Pratesi F., Dioni I., Tommasi C., Alcaro M.C., Paolini I., Barbetti F., et al. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheum Dis 2014, 73:1414-1422.
45. Funk C.D., FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007, 50:470-479.
46. Griffin M.R. High-dose non-steroidal anti-inflammatories: painful choices. Lancet 2013, 382:746-748.
47. Gossec L., Smolen J.S., Gaujoux-Viala C., Ash Z., Marzo-Ortega H., van der Heijde D., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71:4-12.
48. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
49. Jacobsson L.T., Turesson C., Gulfe A., Kapetanovic M.C., Petersson I.F., Saxne T., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1213-1218.
50. van Halm V.P., Nurmohamed M.T., Twisk J.W., Dijkmans B.A., Voskuyl A.E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006, 8:R151.
51. Naranjo A., Sokka T., Descalzo M.A., Calvo-Alen J., Horslev-Petersen K., Luukkainen R.K., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10:R30.
52. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912.
53. Bunescu A., Seideman P., Lenkei R., Levin K., Egberg N. Enhanced Fcγ receptor I, αMβ2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 2004, 31:2347-2355.
54. Pitchford S.C. Novel uses for anti-platelet agents as anti-inflammatory drugs. Br J Pharmacol 2007, 152:987-1002.
55. Arazi H.C., Badimon J.J. Anti-inflammatory effects of anti-platelet treatment in atherosclerosis. Curr Pharm Des 2012, 18:4311-4325.
56. Morrell C.N., Aggrey A.A., Chapman L.M., Modjeski K.L. Emerging roles for platelets as immune and inflammatory cells. Blood 2014, 123:2759-2767.
57. Milovanovic M., Nilsson E., Jaremo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 2004, 343:237-240.
58. Kisacik B., Tufan A., Kalyoncu U., Karadag O., Akdogan A., Ozturk M.A., et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008, 75:291-294.
59. Yazici S., Yazici M., Erer B., Erer B., Calik Y., Ozhan H., et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets 2010, 21:122-125.
60. Yazici S., Yazici M., Erer B., Calik Y., Bulur S., Ozhan H., et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-α therapy decreases the mean platelet volume and platelet mass. Platelets 2010, 21:126-131.
61. Canpolat F., Akpinar H., Eskioglu F. Mean platelet volume in psoriasis and psoriatic arthritis. Clin Rheumatol 2010, 29:325-328.
62. Hutchinson R.M., Davis P., Jayson M.I. Thrombocytosis in rheumatoid arthritis. Ann Rheum Dis 1976, 35:138-142.
63. Farr M., Wainwright A., Salmon M., Hollywell C.A., Bacon P.A. Platelets in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1984, 4:13-17.
64. Endresen G.K. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989, 9:19-24.
65. Egerer K., Hertzer J., Feist E., Albrecht A., Rudolph P.E., Dorner T., et al. sE-selectin for stratifying outcome in rheumatoid arthritis. Arthritis Rheum 2003, 49:546-548.
66. Foster W., Lip G.Y., Raza K., Carruthers D., Blann A.D. An observational study of endothelial function in early arthritis. Eur J Clin Invest 2012, 42:510-516.
67. Knijff-Dutmer E.A., Koerts J., Nieuwland R., Kalsbeek-Batenburg E.M., van de Laar M.A. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002, 46:1498-1503.
68. Wang F., Yan C.G., Xiang H.Y., Xing T., Wang N.S. The significance of platelet activation in ankylosing spondylitis. Clin Rheumatol 2008, 27:767-769.
69. Berckmans R.J., Nieuwland R., Tak P.P., Boing A.N., Romijn F.P., Kraan M.C., et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002, 46:2857-2866.
70. Sari I., Bozkaya G., Kirbiyik H., Alacacioglu A., Ates H., Sop G., et al. Evaluation of circulating endothelial and platelet microparticles in men with ankylosing spondylitis. J Rheumatol 2012, 39:594-599.
71. Wang F., Wang N.S., Yan C.G., Li J.H., Tang L.Q. The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol 2007, 26:768-771.
72. Pamuk G.E., Nuri Pamuk O., Orum H., Arican O., Turgut B., Demir M. Elevated platelet-monocyte complexes in patients with psoriatic arthritis. Platelets 2009, 20:493-497.
73. Littler A.J., Buckley C.D., Wordsworth P., Collins I., Martinson J., Simmons D.L. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, l-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 1997, 36:164-169.
74. Sfikakis P.P., Charalambopoulos D., Vaiopoulos G., Mavrikakis M. Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol 1999, 18:28-32.
75. Ates A., Kinikli G., Turgay M., Duman M. Serum-soluble selectin levels in patients with rheumatoid arthritis and systemic sclerosis. Scand J Immunol 2004, 59:315-320.
76. Wallberg-Jonsson S., Cvetkovic J.T., Sundqvist K.G., Lefvert A.K., Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002, 29:875-882.
77. Daza L., Aguirre M., Jimenez M., Herrera R., Bollain J.J. Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 2007, 26:533-537.
78. Ingegnoli F., Fantini F., Favalli E.G., Soldi A., Griffini S., Galbiati V., et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-α blockade. J Autoimmun 2008, 31:175-179.
79. Maki-Petaja K.M., Cheriyan J., Booth A.D., Hall F.C., Brown J., Wallace S.M., et al. Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int J Cardiol 2008, 129:399-405.
80. Sari I., Okan T., Akar S., Cece H., Altay C., Secil M., et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 2006, 45:283-286.
81. Taylan A., Sari I., Kozaci D.L., Yildiz Y., Bilge S., Coker I., et al. Evaluation of various endothelial biomarkers in ankylosing spondylitis. Clin Rheumatol 2012, 31:23-28.
82. Jonsson S.W., Backman C., Johnson O., Karp K., Lundstrom E., Sundqvist K.G., et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001, 28:2597-2602.
83. Bresnihan B., Roux-Lombard P., Murphy E., Kane D., FitzGerald O., Dayer J.M. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis 2002, 61:726-729.
84. Bodnar N., Kerekes G., Seres I., Paragh G., Kappelmayer J., Nemethne Z.G., et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011, 38:723-729.
85. Irace C., Mancuso G., Fiaschi E., Madia A., Sesti G., Gnasso A. Effect of anti TNF-α therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004, 177:113-118.
86. Galarraga B., Khan F., Kumar P., Pullar T., Belch J.J. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology 2008, 47:1780-1784.
87. Sandoo A., Carroll D., Metsios G.S., Kitas G.D., Veldhuijzen van Zanten J.J. The association between microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2011, 13:R99.
88. van Eijk I.C., Peters M.J., Serne E.H., van der Horst-Bruinsma I.E., Dijkmans B.A., Smulders Y.M., et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009, 68:362-366.
89. Conway E.M., Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. Blood 1993, 81:726-733.
90. Veale D.J., Maple C., Kirk G., McLaren M., Belch J.J. Soluble cell adhesion molecules: P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol 1998, 27:296-299.
91. McEntegart A., Capell H.A., Creran D., Rumley A., Woodward M., Lowe G.D. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001, 40:640-644.
92. Undas A., Gissel M., Kwasny-Krochin B., Gluszko P., Mann K.G., Brummel-Ziedins K.E. Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Thromb Haemost 2010, 104:224-230.
93. Lau C.S., McLaren M., Hanslip J., Kerr M., Belch J.J. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. Ann Rheum Dis 1993, 52:643-649.
94. Wendling D., Racadot E. Serum tissue factor levels correlate with inflammation in ankylosing spondylitis. Joint Bone Spine 2006, 73:403-405.
95. Prati C., Racadot E., Cedoz J.P., Toussirot E., Wendling D. Thrombin generation in rheumatoid arthritis. Joint Bone Spine 2012, 79:522-523.
96. Prati C., Racadot E., Cedoz J.P., Wendling D. Thrombin generation in ankylosing spondylitis. Clin Rheumatol 2011, 30:511-514.
97. Jin T., Tarkowski A., Carmeliet P., Bokarewa M. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther 2003, 5:R9-R17.
98. Farrell A.J., Williams R.B., Stevens C.R., Lawrie A.S., Cox N.L., Blake D.R. Exercise induced release of von Willebrand factor: evidence for hypoxic reperfusion microvascular injury in rheumatoid arthritis. Ann Rheum Dis 1992, 51:1117-1122.
99. Cobankara V., Ozatli D., Kiraz S., Ozturk M.A., Ertenli I., Turk T., et al. Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level. Clin Rheumatol 2004, 23:430-434.
100. Gasparyan A.Y., Sandoo A., Stavropoulos-Kalinoglou A., Kitas G.D. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy. Rheumatol Int 2010, 30:1125-1129.
101. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999, 163:1521-1528.
102. Hurlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., et al. Anti-tumor necrosis factor-a treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
103. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Gonzalez-Gay M.A. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 51:447-450.
104. Bilsborough W., Keen H., Taylor A., O'Driscoll G.J., Arnolda L., Green D.J. Anti-tumour necrosis factor-α therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 2006, 26:1125-1131.
105. Bosello S., Santoliquido A., Zoli A., Di Campli C., Flore R., Tondi P., et al. TNF-α blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 2008, 27:833-839.